ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2026
A simple MRI/PET-derived index predicts relapse-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
aimReliable pretreatment biomarkers for predicting resistance to standard chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) remain lacking. This study evaluated the prognostic value of the tumour area (TA)-to-maximum standardized uptake value (SUVmax) [T/S] ratio, a novel imaging index derived from magnetic resonance imaging (MRI) and
methodWe retrospectively analysed 68 patients with LARC who underwent preoperative CRT followed by curative resection between 2013 and 2024. TA was measured on axial T2-weighted MRI, and SUVmax was obtained from PET-CT. The T/S ratio was calculated as TA/SUVmax. Receiver operating characteristic analysis determined the optimal cut-off for relapse-free survival (RFS). Cox proportional hazards models identified independent prognostic factors. Immunohistochemical analysis of L-type amino acid transporter 1 (LAT1) was performed in 33 patients without CRT to explore biological relevance.
resultsThe T/S ratio showed superior predictive accuracy for RFS (area under the curve, 0.714) than for TA (0.616) and SUVmax (0.574). Patients with a high T/S ratio (cut-off 55.81) demonstrated significantly poorer 3-year RFS (51.8% vs. 84.0%, p = 0.002). Multivariate analysis confirmed high T/S ratio as an independent RFS predictor (HR 4.59; 95% CI: 1.27-16.55; p = 0.019). Tumours with high T/S ratios tended to exhibit elevated LAT1 expression, potentially reflecting a CRT-resistant phenotype.
conclusionsThe pretreatment T/S ratio is a simple, noninvasive biomarker that independently predicts RFS in patients with LARC undergoing CRT. This index may assist in risk stratification and individualized neoadjuvant strategy selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.